IAP4 _ BIRC5
- Known as:
- IAP4 _ BIRC5
- Catalog number:
- AP07514PU-N
- Product Quantity:
- 50 µg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- IAP4 _ BIRC5
Related genes to: IAP4 _ BIRC5
- Gene:
- BIRC5 NIH gene
- Name:
- baculoviral IAP repeat containing 5
- Previous symbol:
- API4
- Synonyms:
- EPR-1, survivin
- Chromosome:
- 17q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-06-10
- Date modifiied:
- 2016-10-04
Related products to: IAP4 _ BIRC5
Related articles to: IAP4 _ BIRC5
- Whole-genome doubling (WGD) is a common yet poorly understood event associated with poor clinical outcomes. Here, we characterize mechanisms by which WGD drives tumor evolution, utilizing mouse mammary tumor models of WGD established through cell fusion. We find that WGD increases transcriptomic and epigenetic heterogeneity and identify the YM155 BIRC5 inhibitor as a compound specifically suppressing WGD+ tumors. WGD triggers immune evasion by escaping CD8 T cell responses, rendering WGD+ tumors more sensitive to anti-PD-L1. Through single-cell profiling, we discover that WGD+ cancer cells exhibit reduced antigen presentation and response to IFNγ, attributed to the epigenetic silencing of MHCI transcriptional regulators via elevated histone H3 lysine 27 trimethylation. Further investigations reveal decreased KDM6 activity and increased succinate levels in WGD+ tumors. PRC2 inhibition preferentially suppresses WGD+ tumor growth, enhances antigen presentation, and CD8 T cell infiltration. Our results underscore metabolic and epigenetic alterations as critical drivers of WGD-associated immune escape. - Source: PubMed
Publication date: 2026/05/07
Foidart PierreLi ZheqiCai XinranSeehawer MarcoBrown Daniel DTawawalla AmatullahBaldominos PilarParvin SalmaNishida JunRojas-Jimenez ErnestoBui Triet MDiciaccio BenedettoKumar RahulSchlegel Brent TGoyette Marie-AnneScales TashJaeYan PengzeQiu XintaoLi RongJiang YijiaXie YingtianAarabi MahmoudHuang Xiao-YunStevens Laura ECejas PalomaMangiante LiseSotomayor Vivas Cristina IreneHoulahan Kathleen ECurtis ChristinaOesterreich SteffiHarris Isaac SLetai Anthony GLee Adrian VLong Henry WAgudo JudithPolyak Kornelia - Lip and oral cavity cancers are among the most common types of cancer worldwide and remain a major health problem due to poor prognosis and treatment- related side effects. Therefore, identifying new naturally derived compounds with selective cytotoxic effects on oral cancer cells is essential. Vulpinic acid, a lichenderived secondary metabolite, has shown antioxidant and anticancer activities in various cancer types. However, its effects on oral cancer cells have not yet been clarified. This study aims to investigate the cytotoxic and apoptotic effects of vulpinic acid on oral cancer cells and to explore its possible molecular mechanisms. - Source: PubMed
Publication date: 2026/05/04
Şengüm Dilara NurAlkan Ayşe HaleBozkurt Fatma ZeynepMutlu PelinCansaran-Duman Demet - BIRC5 (survivin), an inhibitor of apoptosis protein, is overexpressed in most tumors and is associated with drug resistance, proliferation, and metastasis, while being largely undetectable in normal differentiated tissues. This unique expression pattern makes BIRC5 an exceptionally selective therapeutic target, offering the potential to maximize anticancer efficacy while minimizing systemic toxicity to healthy tissues. However, few BIRC5-targeted agents have advanced to late-stage clinical trials. - Source: PubMed
Publication date: 2026/04/28
Chang Yung-ChiehHuang Wei-LunSu Wu-ChouLeung EuphemiaCheng Fong-YuCheung Chun Hei Antonio - : We previously pioneered a multigene mRNA test, qMIDS, validated through an international multicohort study with geographically and ethnically diverse oral squamous cell carcinoma (OSCC) patients from Europe and Asia. This study aimed to repurpose the qMIDS test for nasopharyngeal carcinoma (NPC). A molecular test independent of Epstein-Barr virus (EBV) status would be clinically useful for risk stratification in NPC patients with undetectable or low levels of EBV. : This study investigated a Chinese cohort of 62 participants (18 donated normal nasopharyngeal mucosa (NPM) and 44 donated NPC tissue samples). Messenger RNA levels of 16 genes in each sample were quantified using the qPCR method, and an algorithm computed a malignancy index for cancer risk stratification. : We identified a unique 10-gene panel (containing eight target genes, namely NEK2, INHBA, FOXM1, TOP2A, BIRC5, CXCL8, NR3C1, and IVL, relative to two reference genes, YAP1 and POLR2A, collectively named qMIDS) that demonstrated the best overall diagnostic performance in segregating NPM from NPC, with AUC = 0.909 and positive/negative predictive values of 91% PPV and 78% NPV, respectively. Furthermore, we demonstrated prognostic value of qMIDS in segregating NPM from NPC stage III + IV, with AUC = 0.936, 92% PPV, and 84% NPV. : Here, we present a simple qPCR-based 10-gene mRNA test, qMIDS, with potential clinical utilities for rapid (1 h) prognostic stratification of NPC. Further studies involving geographically and ethnically independent NPC cohorts would be needed to validate the clinical use of qMIDS in non-endemic NPC populations. - Source: PubMed
Publication date: 2026/04/09
Liang YingyingMo ZhiwenTeh Muy-Teck - Hepatocellular carcinoma (HCC) presents with poor treatment outcomes, creating an urgent need for novel biomarkers to improve diagnosis, prognosis, and precision medicine. While the MYB family of oncogenes is implicated in cancer, the role and regulatory mechanisms of its member, particularly MYB proto-oncogene like 2 (MYBL2), remain underexplored in HCC. Therefore, this study aimed to systematically validate the clinical significance of MYBL2, elucidate its functional role in tumor progression and drug sensitivity, and identify its upstream regulatory mechanisms using an integrative machine learning and experimental framework. - Source: PubMed
Publication date: 2026/04/22
Yang Ya-LingHuang Ying-HsienLin Hung-Yu